About: Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()
Creator	Sagel, Scott Accurso, Frank Hoppe, Jordana Wagner, Brandie Zemanick, Edith
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Pulmonary exacerbations (PEx) in children with cystic fibrosis (CF) are frequently treated in the outpatient setting with oral antibiotics. However, little is known about the characteristics of PEx managed on an outpatient basis and the effectiveness of oral antibiotic therapy. We sought to prospectively evaluate clinical and laboratory changes associated with oral antibiotic treatment for PEx. METHODS: Children with CF between 8 and 18 years of age prescribed two weeks of oral antibiotics for a PEx were eligible to enroll. The study consisted of a visit within 48 h of starting antibiotics and a second visit within one week of antibiotic completion. Twenty-eight participants were evaluated by exacerbation score, quality of life measurements, lung function, sputum microbiology and inflammation. RESULTS: Oral antibiotic treatment was associated with a significant improvement in exacerbation score and quality of life measured by the CF Questionnaire-Revised (CFQ-R) respiratory domain. Following treatment, forced expiratory volume in 1 s (FEV(1)) % predicted increased [median (range)] 9% (−8%, 31%), and 22 (81%) subjects returned to 90% or higher of baseline FEV(1). Bacterial density of the primary organism identified on sputum culture decreased significantly with a median (range) decrease of 0.8 log(10) cfu/mL (−8 log(10), 2 log(10,) p = 0.03). Sputum neutrophil elastase [−37 μg/mL (−464, 272), p = 0.02] and IL-1β [−2.8 × 10(3)μg/mL (−6.9 × 10(4), 3.3 × 10(4)), p = 0.03] decreased significantly following treatment in this cohort. CONCLUSIONS: Treatment of PEx with oral antibiotics was associated with measurable improvements in patient reported outcomes, lung function, bacterial density and sputum inflammatory markers.
has issue date	2018-06-18(xsd:dateTime)
bibo:doi	10.1016/j.jcf.2018.05.015
bibo:pmid	29921503
has license	no-cc
sha1sum (hex)	3c79fbac556b84249447c7e2cef2c659f0835654
schema:url	https://doi.org/10.1016/j.jcf.2018.05.015
resource representing a document's title	Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()
has PubMed Central identifier	PMC7105204
has PubMed identifier	29921503
schema:publication	J Cyst Fibros
resource representing a document's body	covid:3c79fbac556b84249447c7e2cef2c659f0835654#body_text
is schema:about of	named entity 'measurements' named entity 'sputum culture' named entity 'higher' named entity 'Results' named entity 'oral' named entity 'treated' named entity 'measurable' named entity 'MEASUREMENTS' named entity 'MICROBIOLOGY' named entity 'MANAGED' named entity 'INCREASED' named entity 'ANTIBIOTIC' named entity 'EUROPEAN' named entity '90%' named entity '3.3' named entity 'KNOWN' named entity 'EXACERBATION' named entity 'PREDICTED' named entity 'CLINICAL' named entity 'BACKGROUND' named entity 'SECOND' named entity 'FORCED EXPIRATORY VOLUME' named entity '9237' named entity 'CHANGES' named entity 'EVALUATE' named entity 'ORAL ANTIBIOTIC THERAPY' named entity 'AGE' named entity 'ASSOCIATED WITH' named entity 'BACTERIAL' named entity 'STUDY' named entity 'MEASURABLE' named entity '928' named entity 'CFU' named entity 'QUESTIONNAIRE' named entity 'PRESCRIBED' named entity 'INFLAMMATION' named entity 'LABORATORY' named entity 'STARTING' named entity 'OUTPATIENT' named entity 'PUBLISHED' named entity 'FEV 1' named entity 'RESPIRATORY DOMAIN' named entity 'ANTIBIOTIC TREATMENT' named entity 'CHILDREN' named entity 'SUBJECTS' named entity 'SETTING' named entity 'REVISED' named entity '926' named entity 'LITTLE' named entity 'SOCIETY' named entity 'ABOUT' named entity 'ELIGIBLE' named entity 'DECREASED' named entity 'METHODS' named entity 'PATIENT REPORTED OUTCOMES' named entity 'BASIS' named entity 'COMPLETION' named entity 'CHARACTERISTICS' named entity 'ORGANISM' named entity 'YEARS' named entity 'TWENTY-EIGHT' named entity 'EFFECTIVENESS' named entity '0.03' named entity 'MEASURED' named entity 'ORIGINAL' named entity 'ARTICLE' named entity 'PARTICIPANTS' named entity 'PULMONARY' named entity 'NEUTROPHIL ELASTASE' named entity 'RETURNED' named entity 'FREQUENTLY' named entity 'IDENTIFIED' named entity 'IL-1' named entity 'TREATED' named entity 'SCORE' named entity '0.02' named entity 'PEX'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software